Amryt Pharma has been handed a major blow by the FDA, after the US regulator rejected its marketing application for Oleogel-S10, its drug for rare and debilitating skin disease epidermolysi
Rare disease specialist Amryt Pharma plans to expand its rare disease portfolio with the acquisition of troubled Aegerion Pharmaceuticals, a division of Canada’s Novelion.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
